cbdMD Inc.
Find Ratings ReportsCBDMD INC's gross profit margin for the first quarter of its fiscal year 2024 has increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. CBDMD INC has very weak liquidity. Currently, the Quick Ratio is 0.44 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 73.53% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q1 FY24 | Q1 FY23 |
---|---|---|
Net Sales ($mil) | 5.38 | 6.09 |
EBITDA ($mil) | -0.78 | -2.78 |
EBIT ($mil) | -1.07 | -3.16 |
Net Income ($mil) | -1.0 | -3.96 |
Balance Sheet | Q1 FY24 | Q1 FY23 |
---|---|---|
Cash & Equiv. ($mil) | 1.51 | 4.35 |
Total Assets ($mil) | 15.1 | 35.73 |
Total Debt ($mil) | 3.37 | 4.58 |
Equity ($mil) | 7.04 | 26.59 |
Profitability | Q1 FY24 | Q1 FY23 |
---|---|---|
Gross Profit Margin | 66.18 | 58.64 |
EBITDA Margin | -14.56 | -45.75 |
Operating Margin | -19.85 | -51.95 |
Sales Turnover | 1.55 | 0.9 |
Return on Assets | -132.35 | -153.6 |
Return on Equity | -340.77 | -221.44 |
Debt | Q1 FY24 | Q1 FY23 |
---|---|---|
Current Ratio | 1.23 | 2.08 |
Debt/Capital | 0.32 | 0.15 |
Interest Expense | 0.0 | 0.0 |
Interest Coverage | 0.0 | 0.0 |
Share Data | Q1 FY24 | Q1 FY23 |
---|---|---|
Shares outstanding (mil) | 2.96 | 1.35 |
Div / share | 0.0 | 0.0 |
EPS | -0.67 | -3.6 |
Book value / share | 2.38 | 19.71 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 771583.0 | 23196.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 0.30 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 19.07. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, CBDMD INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
YCBD NM | Peers 85.83 | YCBD 17.20 | Peers 38.76 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. YCBD's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. YCBD is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
YCBD NM | Peers 18.08 | YCBD NA | Peers 1.16 | |||||||||||||||||||||
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. YCBD's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
YCBD 0.30 | Peers 19.07 | YCBD 79.12 | Peers 12.58 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. YCBD is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. YCBD is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
YCBD 0.09 | Peers 84.44 | YCBD -27.12 | Peers 42.35 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. YCBD is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. YCBD significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||